TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03238053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser system
Description: FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser system
Description: FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser system
Description: FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
Study: NCT06089317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCM ultrasonic atomization treatment with herbal Compound Decoction (CD)
Description: The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the CD group is TCM compound decoction.~The prescription of atomization solution in the CD group contains Honeysuckle flower (金銀花) 5g, Chrysanthemum flower (菊花) 5g, Pale betterflybush flower (密蒙花) 5g, Mild mint herb (薄荷) 5g, Barbary wolfberry fruit (枸杞子) 10g, and Ophiopogon japonicus (麥冬) 5g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCM ultrasonic atomization treatment with Dendrobii Caulis (DC)
Description: The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the DC group is Dendrobii Caulis extracts.~The prescription of the DC group contains Dendrobium (石斛) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCM ultrasonic atomization treatment with Houttuynia Cordata (HC)
Description: The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the HC group is Heartleaf Houttuynia Herb extracts.~The prescription of the HC group contains Heartleaf Houttuynia Herb(魚腥草) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TCM ultrasonic atomization treatment (PA)
Description: The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the PA group is low-concentration compound decoction (5%) same with the CD group.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too.

Intervention type: DRUG
Group type: OTHER
Intervention: Artificial Tears (AT)
Description: The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Tears (AT)
Description: The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Tears (AT)
Description: The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.
Study: NCT05660681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol 400 0.4%/propylene glycol 0.3%
Description: Eye drop with active agents from the OTC Monograph.
Study: NCT06089317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Tears (AT)
Description: The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Tears (AT)
Description: The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.
Study: NCT04693377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryoablation
Study: NCT06696378

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg
Description: wo capsules per day; Each capsule includes 3mg Melatonin Nutrifoods® Laboratories, Barcelona, Spain) by the Magistral Formulation Laboratory of a Pharmacy (Soria, Spain), following the rules of the Royal Spanish Pharmacopoeia (Ministry of Health, Government of Spain). Melatonin has a technical data sheet that guarantees its composition and purity (Reference No.: DIE-134).
Study: NCT05995119

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)
Description: The subjects were administered either the test (TAH3311 5 mg ODF as Treatment T1) or reference (ELIQUIS® 5 mg oral tablet as Treatment R1) product at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In the other two study periods, the subjects were administered either the test (Treatment T2) or reference (Treatment R2) product following an overnight fast of at least 10 hours. The subjects received the test and reference products in accordance with a four-sequence randomization schedule. There was a washout period of 5 days between the dosing days of any two consecutive periods.

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)
Description: The subjects were administered either the test (TAH3311 5 mg ODF as Treatment T1) or reference (ELIQUIS® 5 mg oral tablet as Treatment R1) product at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In the other two study periods, the subjects were administered either the test (Treatment T2) or reference (Treatment R2) product following an overnight fast of at least 10 hours. The subjects received the test and reference products in accordance with a four-sequence randomization schedule. There was a washout period of 5 days between the dosing days of any two consecutive periods.
Study: NCT06393036

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. Although the study is designed as an observational cohort study, where patients self-selected whether to receive treatment rather than being assigned, there is still an intervention project, CPAP, present in the observational cohort. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
Study: NCT05667194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH617
Description: KH617 is s freeze-dried powder injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH617
Description: KH617 is s freeze-dried powder injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH617
Description: KH617 is s freeze-dried powder injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH617
Description: KH617 is s freeze-dried powder injection
Study: NCT06696378

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Melatonin tablets to ensure blinding.
Study: NCT06697327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Daunorubicin, Cytarabine, Venetoclax)
Description: * Drugs：Daunorubicin~  * Dosage: 40 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs：Cytarabine~  * Dosage: 100 mg/(m²·d) on days 1 to 5~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U~* Drugs：Venetoclax~  * Dosage: 100 mg on day 1, 200 mg on day 2, and 400 mg from days 3 to 14~ * Other names: ABT-199, Venclexta, Venclyxto

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Daunorubicin, Cytarabine)
Description: * Drugs：Daunorubicin~  * Dosage: 60 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs：Cytarabine~  * Dosage: 100 mg/(m²·d) on days 1 to 7~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U
Study: NCT06698055

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flywheel Resistance Exercise
Description: FW is conducted in a leg extension machine (LegExx, Exxentric, Stockholm, Sweden) and leg press machine (YoYo™ Leg Press, nHANCE, Sweden).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flywheel Resistance Exercise
Description: FW is conducted in a leg extension machine (LegExx, Exxentric, Stockholm, Sweden) and leg press machine (YoYo™ Leg Press, nHANCE, Sweden).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Stack Resistance Exercise
Description: WS is conducted in a leg extension machine (Seated leg press, Nordic Gym, Bollnäs, Sweden) and a leg press machine (Seated leg extension, Nordic Gym, Bollnäs, Sweden)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Stack Resistance Exercise
Description: WS is conducted in a leg extension machine (Seated leg press, Nordic Gym, Bollnäs, Sweden) and a leg press machine (Seated leg extension, Nordic Gym, Bollnäs, Sweden)
Study: NCT06711887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: Ianalumab (VAY736) is a human monoclonal antibody (mAb) of the IgG1/κ-class, directed against B cells and binding to BAFF receptor (BAFF-R).
Study: NCT06707935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Descriptive social norm nudges
Description: A set of messages with descriptive social norm nudges sent to participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pictorial social norm nudges
Description: A set of messages with pictorial social norm nudges sent to participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Service as usual
Description: Traditional mental health education information disseminated to participants.
Study: NCT06711224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention for adolscents with ADHD
Description: The aim of the digital intervention is to promote coping of ADHD. The intervention has a duration of 6 weeks and will be delivered as a mobile app including weekly phone calls from a therapist. The intervention includes text, interactive exercises, animations, and coping skills. The themes of the intervention includes psychoeducation on ADHD, healthy habits (sleep, exercise, food), social skills, and emotion regulation. The adolescents have the possibility to choose some of the themes they want to work on during the intervention.
Study: NCT06707675

Intervention type: OTHER
Intervention: Assessment
Description: The patients' demographic information, weight and height measurements, occupational activities and desk work time, daily screen usage time, pain intensity (with VAS), cervical joint range of motion examination, pain threshold (with pressure algometer), functional status (with Neck Pain Disability Scale), sleep quality (with Pittsburgh Sleep Quality Scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspects of pain (with Pain Catastrophizing Scale) will be evaluated. The patients' chronotype preferences will be evaluated with Morningness Eveningness Questionnaire.
Study: NCT06708832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMBA ingestion
Description: Ingestion of 2 SIMBA capsules at the same time and their excretion.
Study: NCT06707987

Intervention type: DRUG
Intervention: Non-immunogenic staphylokinase
Description: Drug: non-immunogenic staphylokinase 10 mg as a single intravenous bolus Other Names: Fortelyzin®
Study: NCT06712173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linperlisib and SHR2554
Description: Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total.
Study: NCT06711471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab
Description: Patients enrolled in this study will receive trifluridine/tipiracil in combination with bevacizumab and camrelizumab, with a treatment cycle of 14 days, until disease progression, death, intolerable toxicity, or other criteria for discontinuation of study treatment as specified in the protocol (whichever occurs first).
Study: NCT06713772

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA
Description: Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steri-StripsTM (3M, St. Paul, Minnesota, USA
Description: Steri-StripsTM (3M, St. Paul, Minnesota, USA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany
Description: Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany
Study: NCT06713382

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pleural Saline Irrigation
Description: This intervention, Pleural Saline Irrigation, involves the administration of up to 250 mL of sterile saline solution into the pleural cavity through a chest tube immediately following each intrapleural tPA/DNase (IPFT) therapy session. The saline irrigation is intended to aid in clearing infected pleural fluid and reducing pleural effusion volume. This maneuver is repeated based on the treating physician's criteria, differentiating it from standard care, which includes only antibiotics, chest tube placement, and IPFT without saline irrigation. The irrigation is expected to enhance infection resolution and may impact chest tube duration and the frequency of pleural interventions.
Study: NCT04539041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antisense oligonucleotide
Description: solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antisense oligonucleotide
Description: solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antisense oligonucleotide
Description: solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antisense oligonucleotide
Description: solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antisense oligonucleotide
Description: solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for each dose level
Study: NCT06714526

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Point-of-Care CYP2C19 Testing
Description: Genetic testing with the Genomadix cube to determine P2Y12 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor + aspirin
Description: If patients are poor or intermediate metabolizers of clopidogrel, they will receive ticagrelor (90 mg PO BID) + aspirin (81 mg PO daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel + aspirin
Description: Normal, rapid, and ultra-rapid metabolizers of clopidogrel will receive 75 mg PO daily of clopidogrel and 81 mg PO daily of aspirin.
Study: NCT06713148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDOV-SAFETM
Description: Each patient received intratumoral injection on the first day, 14 days as a course of treatment, and the follow-up investigator decided whether to continue the second (D14) and third (D28) course of administration according to the comprehensive evaluation of the subjects' conditions
Study: NCT06711705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Subcutaneous injection of elranatamab. If patient achieves MRD negative remission, patient would enter treatment-free observation period with MRD monitoring.
Study: NCT06466421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine 60 mg orally once daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 100 mg after each dialysis session (thrice weekly). Dose may be titrated after 2 weeks, according to response and tolerability, to 100 mg orally once daily for 3 months.
Study: NCT04960280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ©VoqX stethoscope
Description: Computerized auscultation detects both infrasound and audible sounds and is capable of amplifying auscultated sounds by a factor of thirty.
Study: NCT06360718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Who is Luke Eemia? Storybook
Description: Parents in this group will receive the Who is Luke Eemia? storybook, and will receive guidance from the child life specialist on how to utilize the storybook with their school-aged child. Parents in this study will complete surveys at three timepoints, these surveys include: (1) Comfort Survey (prior to child life intervention), (2) Discharge Survey and (3) Storybook Assessment survey to review the parent's impression of the storybook intervention tool (at the time of discharge, or about 1 week following the child life intervention), and the (4) Parenting Stress Index -4-Short Form (at baseline, at the time of the discharge survey, and about 3.5 months later).
Study: NCT04286555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH4D diet
Description: DASH stands for Dietary Approaches to Stop Hypertension. The DASH diet is a healthy dieter that lowers blood pressure. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages. The DASH4D dietary pattern is a version of the DASH diet that is lower in carbohydrate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH4D diet
Description: DASH stands for Dietary Approaches to Stop Hypertension. The DASH diet is a healthy dieter that lowers blood pressure. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages. The DASH4D dietary pattern is a version of the DASH diet that is lower in carbohydrate.

Intervention type: OTHER
Group type: OTHER
Intervention: comparison diet
Description: The comparison dietary pattern is based on a typical American diet, with macronutrient distributions generally at the average of typical US intake, and micronutrient targets generally near the 25th percentile of usual US intake (with the exception of sodium).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: comparison diet
Description: The comparison dietary pattern is based on a typical American diet, with macronutrient distributions generally at the average of typical US intake, and micronutrient targets generally near the 25th percentile of usual US intake (with the exception of sodium).
Study: NCT04693377

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04286555

Intervention type: OTHER
Group type: OTHER
Intervention: higher sodium
Description: 3700 mg/day sodium (at the 2000 kilocalorie level)
Study: NCT04693377

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo stereotactic body radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo stereotactic body radiation therapy
Study: NCT05884528

Intervention type: BIOLOGICAL
Intervention: CC BoNT/A
Description: Complex-containing BotulinumtoxinA (BoNT/A) formulations

Intervention type: BIOLOGICAL
Intervention: CF BoNT/A
Description: Complex-free BotulinumtoxinA (BoNT/A) formulation

Intervention type: BIOLOGICAL
Intervention: CF to CC BoNT/A
Description: Switch from complex-free to complex-containing BoNT/A formulations
Study: NCT04286555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: higher sodium
Description: 3700 mg/day sodium (at the 2000 kilocalorie level)
Study: NCT05884528

Intervention type: BIOLOGICAL
Intervention: CC to CF BoNT/A
Description: Switch from complex-containing to complex-free BoNT/A formulations
Study: NCT05772156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylergonovine
Description: Methylergonovine 200mcg Intramuscular (IM)
Study: NCT05667194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH617
Description: KH617 is s freeze-dried powder injection